Epidemiology, Value Evidence and Outcomes, Global R&D, GSK, London, UK.
Real World Analytics, Value Evidence and Outcomes, Global Medical, GSK, London, UK.
Immun Inflamm Dis. 2021 Dec;9(4):1447-1451. doi: 10.1002/iid3.495. Epub 2021 Jul 22.
Data on the burden of hypereosinophilic syndrome (HES) are limited. This study investigated the incidence and prevalence of HES using real-world data from patients in the United Kingdom.
Primary care data from the Clinical Practice Research Datalink were analyzed. The patients of interest were identified using medical codes specific for HES. Annual incidence rates and prevalence were estimated for the years 2010-2018 (inclusive) using patients observed for a minimum period of one year.
Between 2010 and 2018, 93 patients were identified with HES. During the study period the incidence of HES ranged from less than 0.04, 95% confidence interval (CI) (0.01-0.07) to 0.17, 95% CI (0.10-0.26) per 100,000 person-years and the prevalence ranged from 0.15, 95% CI (0.10-0.25) to 0.89, 95% CI (0.74-1.09) cases per 100,000 persons. Sensitivity analyses varying the minimum observation period required to identify HES patients gave similar results.
These results provide estimates of the burden of HES in the United Kingdom and indicate that whilst HES is a very rare disease, there is evidence that is increasingly being recorded in UK primary care.
关于嗜酸性粒细胞增多综合征(HES)负担的数据有限。本研究使用来自英国患者的真实世界数据调查了 HES 的发病率和患病率。
对临床实践研究数据链接中的初级保健数据进行了分析。使用特定于 HES 的医疗代码来识别目标患者。使用至少观察一年的患者,估计了 2010 年至 2018 年(包括在内)的年度发病率和患病率。
在 2010 年至 2018 年期间,共确定了 93 例 HES 患者。在研究期间,HES 的发病率范围为每 100,000 人年 0.04 以下,95%置信区间(CI)(0.01-0.07)至 0.17,95%CI(0.10-0.26),患病率范围为每 100,000 人 0.15,95%CI(0.10-0.25)至 0.89,95%CI(0.74-1.09)。改变识别 HES 患者所需的最低观察期的敏感性分析得出了类似的结果。
这些结果提供了英国 HES 负担的估计,并表明尽管 HES 是一种非常罕见的疾病,但有证据表明它在英国初级保健中越来越多地被记录。